Publications by authors named "Oosterlee J"
Article Synopsis
- COVID-19 causes a hypercoagulatory state that can lead to serious blood clot issues, and while anticoagulation helps reduce mortality, the benefits of antiplatelet therapy are uncertain.
- A study of 578 hospitalized COVID-19 patients found no correlation between antiplatelet therapy and survival rates, with adverse outcomes more tied to an overactive coagulation system.
- Analysis of postmortem lung biopsies and patient blood samples indicated that while clotting was problematic, platelet function appeared impaired in severe cases, suggesting that antiplatelet therapy did not improve outcomes and might even worsen platelet issues.
Thromboembolic complications are frequently observed in Coronavirus disease 2019 (COVID-19). While COVID-19 is linked to platelet dysregulation, the association between disease outcome and platelet function is less clear. We prospectively monitored platelet activation and reactivity in 97 patients during the first week of hospitalization and determined plasma markers of platelet degranulation and inflammation.
View Article and Find Full Text PDFIf they do not immediately lead to death, severe injuries of the pelvis and perineum are frequently complicated by serious invasive infection. This results in a considerable number of late deaths. Adherence to a strict treatment protocol aimed at the prevention of septic complications has undoubtedly reduced the mortality rate related to these injuries.
View Article and Find Full Text PDFTwenty patients with malignant ascites were treated by insertion of a peritoneovenous shunt. Twelve had a LeVeen shunt, 7 a Denver shunt and 1 patient had a LeVeen shunt subsequently replaced by a Denver shunt. Overall survival was poor, which reflects the advanced stage of the patients' disease.
View Article and Find Full Text PDF